Track topics on Twitter Track topics that are important to you
TEL AVIV, ISRAEL -- (Marketwired) -- 08/08/17 -- InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today provided a business update, including the successful transition of all territories previously covered by the Company's former European distributor to a local network of regional distributors. The Company also reported financial and operating results for the second quarter ended June 30, 2017.
James Barry, PhD, Chief Executive Officer of InspireMD, commented, "I am pleased to report we successfully completed our transition from a single distributor covering 18 European countries, to now having a direct distribution model with local distributors that have much greater reach into all the relevant clinical specialties and each of their respective markets. Our new distributors share our belief that CGuard can achieve market leadership in all countries where it is available. Moreover, we completed the rollout on schedule and there has been tremendous support from the top key opinion leaders (KOL) in each of these markets. In fact, CGuard sales in these specific European countries increased 122% sequentially versus the first quarter of 2017."
"With our European distribution network in place, we are now focusing our efforts on expansion into other markets around the world. Most recently, we signed an agreement with a leading distributor in Taiwan. This follows a similar agreement in Hong Kong earlier this year, and we are in talks with a number of distributors across Asia to further expand our footprint. We expect to make additional announcements on this subject in the coming months. We also announced recent agreements in Peru and Ecuador, and our plan is to continue to expand our presence in Central and South America. CGuard is a platform technology that can be transferred to a number of other products, and building this global distributor network should allow us to launch new products quickly and efficiently as our pipeline develops over the coming years."
"We also continue to report new data and are gaining significant attention from top KOLs around the world. In May, we reported publication of the investigator initiated IRON-GUARD Italian clinical registry in the peer reviewed journal EuroIntervention. IRON-GUARD was an independent, multicenter, multi-disciplinary clinical study treating patients with carotid artery disease using the CGuard EPS in 12 Italian centers. The IRON-GUARD registry enrolled 200 patients, and showed results of 100% technical success placing the device, and zero incidence of major adverse cardiovascular events (MACE), comprised of death, major stroke or myocardial infarction, in all patients at 30 days. Also in May, we were honored to have the team of Professor Alberto Cremonesi, Chief of the Cardiovascular Department and Director of the Interventional Cardiovascular Unit of Maria Cecilia Hospital - GVM Care & Research, Cotignola (Italy), perform a live endovascular interventional procedure featuring the CGuard EPS Carotid Stent at EuroPCR 2017. The case was transmitted real time to the entire congress. EuroPCR is the world's leading course in interventional cardiovascular medicine bringing together over 12,000 clinicians and industry executives each year."
Dr. Barry concluded, "We remain extremely encouraged by the favorable response from leading medical practitioners around the world. Now that we have a robust distribution network in place across Europe, we believe we have a highly scalable and cost-effective platform to grow sales. We plan to replicate this model around the world. Overall, we achieved solid double-digit year-over-year and sequential revenue growth, which we expect to continue in the second half of the year. We also remain focused on carefully managing expenses and driving shareholder value. We appreciate the patience and support of our shareholders, and look forward to announcing additional significant milestones in the months ahead."
Revenue for the second quarter ended June 30, 2017 was $640,000 compared to $540,000 during the same period in 2016. The increase was primarily due to an increase in sales of CGuard EPS as we entered new regional markets during the transition from our prior exclusive distribution partner for most of Europe. The transition to local distributors reflects an effort to broaden our sales efforts from only interventional neuroradiologists to include vascular surgeons, interventional cardiologists and interventional radiologists, as well. In addition to the increase in sales of CGuard EPS, sales of MGuard Prime EPS slightly increased, as well. Total operating expenses for the quarter ended June 30, 2017 were $2,441,000, an increase of 33.5% compared to $1,828,000 for the same period in 2016. This increase was primarily due to an increase in sales and marketing expenses (primarily to support the commercialization of CGuard EPS), as well as an increase in salary expenses primarily due to a non-cash accrual adjustment. Net loss for the quarter ended June 30, 2017 totaled $2,294,000, or $0.21 per basic and diluted share, compared to a net loss of $1,946,000, or $4.56 per basic and diluted share, in the same period in 2016.
Revenue for the six months ended June 30, 2017 was $1,209,000 compared to $1,103,000 during the same period in 2016. The increase was predominantly driven by the increase in sales of CGuard EPS offset by a decrease in sales of MGuard Prime EPS associated with the trend of doctors increasingly using drug eluting stents (DES) rather than bare metal stents in STEMI patients. Total operating expenses for the six months ended June 30, 2017 were $4,919,000, an increase of 25.4% compared to $3,924,000 for the same period in 2016. This increase was primarily due to an increase in sales and marketing expenses (primarily to support the commercialization of CGuard EPS), as well as an increase in salary expenses primarily due to a non-cash accrual. Net loss for the six months ended June 30, 2017 totaled $4,853,000, or $0.73 per basic and diluted share, compared to a net loss of $4,198,000, or $11.21 per basic and diluted share, in the same period in 2016.
As of June 30, 2017, cash and cash equivalents were $6,879,000, compared to $7,516,000 as of December 31, 2016.
The Company will host a conference call on Wednesday, August 9 at 8:00 a.m. Eastern Time. The conference call will be available via telephone by dialing toll free 866-682-6100 for U.S. callers or +1 862-255-5401 for international callers, or on the Company's Investor Relations section of the website: http://www.inspiremd.com/en/investors/investor-relations/.
A webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately one hour following the call, through midnight August 23, 2017, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 15963.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants are quoted on the NYSE MKT under the ticker symbol NSPR.WS.
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 FREE Email: Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...